Abstract

Small cell osteosarcoma (SCO) is a rare subtype of osteosarcoma characterized by highly aggressive progression and a poor prognosis. The miRNA and mRNA expression profiles of peripheral blood mononuclear cells (PBMCs) were obtained in 3 patients with SCO and 10 healthy individuals using high-throughput RNA-sequencing. We identified 37 dysregulated miRNAs and 1636 dysregulated mRNAs in patients with SCO compared to the healthy controls. Specifically, the 37 dysregulated miRNAs consisted of 27 up-regulated miRNAs and 10 down-regulated miRNAs; the 1636 dysregulated mRNAs consisted of 555 up-regulated mRNAs and 1081 down-regulated mRNAs. The target-genes of miRNAs were predicted, and 1334 negative correlations between miRNAs and mRNAs were used to construct an miRNA-mRNA regulatory network. Dysregulated genes were significantly enriched in pathways related to cancer, mTOR signaling and cell cycle signaling. Specifically, hsa-miR-26b-5p, hsa-miR-221-3p and hsa-miR-125b-2-3p were significantly dysregulated miRNAs and exhibited a high degree of connectivity with target genes. Overall, the expression of dysregulated genes in tumor tissues and peripheral blood samples of patients with SCO measured by quantitative real-time polymerase chain reaction corroborated with our bioinformatics analyses based on the expression profiles of PBMCs from patients with SCO. Thus, hsa-miR-26b-5p, hsa-miR-221-3p and hsa-miR-125b-2-3p may be involved in SCO tumorigenesis.

Highlights

  • Osteosarcoma (OS) is a common primary bone tumor in young adults and adolescents [1], which is characterized by a high metastatic potential: approximately 20–25% of newly diagnosed patients harbor detectable lung-related metastases [2, 3]

  • The mRNA and miRNA expression profiles of peripheral blood samples from patients with Small cell osteosarcoma (SCO) were obtained via RNA sequencing

  • Dysregulated mRNAs and miRNAs were identified in silico, and the expression levels of candidate mRNAs and miRNAs in both tumor tissues and peripheral blood samples from patients with SCO were verified by Quantitative real-time polymerase chain reaction (qRT-PCR)

Read more

Summary

Introduction

Osteosarcoma (OS) is a common primary bone tumor in young adults and adolescents [1], which is characterized by a high metastatic potential: approximately 20–25% of newly diagnosed patients harbor detectable lung-related metastases [2, 3]. Despite recent improvements in therapeutic strategies, including surgical, radiotherapy and neoadjuvant chemotherapy, the 5-year survival of patients with OS remains below 70% [4]. Small-cell osteosarcoma (SCO) is a rare subtype of OS and accounts for less than 1% of OS cases [5]. SCO is highly aggressive and frequently found in the metaphyses of long bones, which results in a poor prognosis. SCO presents as small, round, primitive, and undifferentiated cells with osteoid production [6]. SCO does not respond to radiotherapy and is more aggressive than other subtypes of OS [7]. Novel therapeutic strategies for patients with SCO are urgently needed

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call